Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Gains from Sales and Divestitures (2019 - 2023)

Historic Gains from Sales and Divestitures for Korro Bio (KRRO) over the last 5 years, with Q3 2023 value amounting to $1.6 million.

  • Korro Bio's Gains from Sales and Divestitures rose 19561.16% to $1.6 million in Q3 2023 from the same period last year, while for Sep 2023 it was $1.6 million, marking a year-over-year increase of 19561.16%. This contributed to the annual value of $551450.0 for FY2022, which is 5932349.14% up from last year.
  • Latest data reveals that Korro Bio reported Gains from Sales and Divestitures of $1.6 million as of Q3 2023, which was up 19561.16% from $673900.0 recorded in Q2 2023.
  • Korro Bio's 5-year Gains from Sales and Divestitures high stood at $1.6 million for Q3 2023, and its period low was $464.0 during Q3 2020.
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $226519.0 (2019), whereas its average is $292589.2.
  • In the last 5 years, Korro Bio's Gains from Sales and Divestitures plummeted by 9979.52% in 2020 and then surged by 6683965.52% in 2022.
  • Quarter analysis of 5 years shows Korro Bio's Gains from Sales and Divestitures stood at $275243.0 in 2019, then plummeted by 75.56% to $67273.0 in 2020, then tumbled by 98.62% to $928.0 in 2021, then skyrocketed by 59323.49% to $551450.0 in 2022, then surged by 195.61% to $1.6 million in 2023.
  • Its Gains from Sales and Divestitures stands at $1.6 million for Q3 2023, versus $673900.0 for Q2 2023 and $306775.0 for Q1 2023.